![Distinct antibody clones detect PD-1 checkpoint expression and block PD-L1 interactions on live murine melanoma cells | Scientific Reports Distinct antibody clones detect PD-1 checkpoint expression and block PD-L1 interactions on live murine melanoma cells | Scientific Reports](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41598-022-16776-1/MediaObjects/41598_2022_16776_Fig6_HTML.png)
Distinct antibody clones detect PD-1 checkpoint expression and block PD-L1 interactions on live murine melanoma cells | Scientific Reports
![Oncolytic measles vaccines encoding PD-1 and PD-L1 checkpoint blocking antibodies to increase tumor-specific T cell memory: Molecular Therapy - Oncolytics Oncolytic measles vaccines encoding PD-1 and PD-L1 checkpoint blocking antibodies to increase tumor-specific T cell memory: Molecular Therapy - Oncolytics](https://www.cell.com/cms/asset/ddf09c3c-4d1d-487e-bc5f-a562f8f98a94/fx1.jpg)
Oncolytic measles vaccines encoding PD-1 and PD-L1 checkpoint blocking antibodies to increase tumor-specific T cell memory: Molecular Therapy - Oncolytics
![Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo | Nature Biotechnology Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo | Nature Biotechnology](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fnbt.4195/MediaObjects/41587_2018_BFnbt4195_Fig1_HTML.jpg)
Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo | Nature Biotechnology
![Formatting and gene-based delivery of a human PD-L1 single domain antibody for immune checkpoint blockade: Molecular Therapy Methods & Clinical Development Formatting and gene-based delivery of a human PD-L1 single domain antibody for immune checkpoint blockade: Molecular Therapy Methods & Clinical Development](https://www.cell.com/cms/attachment/4711be6c-7290-4ebd-bd34-58e1364a2c63/fx1_lrg.jpg)
Formatting and gene-based delivery of a human PD-L1 single domain antibody for immune checkpoint blockade: Molecular Therapy Methods & Clinical Development
![Frontiers | A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy Frontiers | A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy](https://www.frontiersin.org/files/Articles/654463/fimmu-12-654463-HTML/image_m/fimmu-12-654463-g001.jpg)
Frontiers | A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy
![PD‐1‐specific “Blocking” antibodies that deplete PD‐1+ T cells present an inconvenient variable in preclinical immunotherapy experiments - Polesso - 2021 - European Journal of Immunology - Wiley Online Library PD‐1‐specific “Blocking” antibodies that deplete PD‐1+ T cells present an inconvenient variable in preclinical immunotherapy experiments - Polesso - 2021 - European Journal of Immunology - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/c8564ea5-e0fc-4761-9f10-a3e9b9668b9a/eji5016-fig-0002-m.jpg)
PD‐1‐specific “Blocking” antibodies that deplete PD‐1+ T cells present an inconvenient variable in preclinical immunotherapy experiments - Polesso - 2021 - European Journal of Immunology - Wiley Online Library
Synergistic anti-tumor efficacy by combination therapy of a self-assembled nanogel vaccine with an immune checkpoint anti-PD-1 antibody - RSC Advances (RSC Publishing)
![Anti-PD-1 Blocking Antibody Inhibits Human Melanoma Xenograft Growth in... | Download Scientific Diagram Anti-PD-1 Blocking Antibody Inhibits Human Melanoma Xenograft Growth in... | Download Scientific Diagram](https://www.researchgate.net/publication/281679913/figure/fig5/AS:302618359418892@1449161247481/Anti-PD-1-Blocking-Antibody-Inhibits-Human-Melanoma-Xenograft-Growth-in-Immunocompromised.png)
Anti-PD-1 Blocking Antibody Inhibits Human Melanoma Xenograft Growth in... | Download Scientific Diagram
![Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy - ScienceDirect Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1535610821004025-fx1.jpg)